Clinical Trial Update: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout [Phase 4]

View source ↗

Summary

This completed Phase 4 trial assessed whether pegloticase given every 4 weeks with methotrexate is non-inferior to pegloticase every 2 weeks with methotrexate i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Krystexxa (pegloticase) (pegloticase)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Amgen | Conditions: Gout | Phase 4 | Status: COMPLETED